BioNTech to pay €20M upfront, pick equity stake in Ryvu in license deal to boost cancer portfolio [Seeking Alpha]
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: Seeking Alpha
BioNTech to pay â?¬20M upfront, pick equity stake in Ryvu in license deal to boost cancer portfolioNov. 30, 2022 5:39 AM ETBioNTech SE (BNTX)By:RavikashSA News Editor2 CommentsU. J. AlexanderGermany's BioNTech (NASDAQ:signedThe global collaboration will consist of two parts: BioNTech will receive a global, exclusive license to developand commercialize Ryvu's STING agonist portfolio as standalone small molecules, including as monotherapy and in therapeutic combinations.In addition, BioNTech and Ryvu will jointly undertake drug discovery and research projects to develop multiple small molecule programs aimed at exclusive targets selected by BioNTech, mainly focused on immune modulation within oncology, with potential applications in other disease areas.BioNTech has the option to license global development and commercialization rights to the programs at the development stage, the companies said.Under the agreement, BioNTech will pay â?¬20M upfront in exchange for certain rights to Ryvuâ?
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $107.00 price target on the stock.MarketBeat
- Fragmented Europe to make new bid for US-style capital market [Reuters]Reuters
- Pfizer wins pause on Moderna's COVID-19 patent lawsuit [Reuters]Reuters
- Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1' immune cell engager CB699 at AACR 2024 [Yahoo! Finance]Yahoo! Finance
- Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting [Yahoo! Finance]Yahoo! Finance
BNTX
Earnings
- 3/20/24 - Miss
BNTX
Sec Filings
- 4/8/24 - Form 6-K
- 4/8/24 - Form 6-K
- 3/25/24 - Form 6-K
- BNTX's page on the SEC website